drugset / Trial / NCT00034853

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

NCT00034853

Phase 3 Completed 180 enrolled Boehringer Ingelheim
Parallel-groupTreatment

Summary

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

Timeline

Start
2000-12
Primary completion
2003-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule Oral
Subject Naproxen Small molecule Oral